Tamoxifen also significantly inhibited the proliferative effects of DPN in all 4 bladder cancer cell lines (Fig. 3C-F) when the two treatments were combined, supporting the therapeutic efficacy of selective ER modulators in bladder cancer. This evidence concerns the gene ESR1 and urinary bladder cancer.